Exacis Biotherapeutics
Cambridge, US · Founded 2020 · Delaware corporation
Founders & leadership
GF
Gregory FioreChief Executive Officer
MA
Matthew AngelNamed on SEC filing
MC
Mark CorriganNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.2M disclosed across 2 rounds · 2020–2021
▶$50KraisedFeb 2021 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedFeb 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark CorriganDirector
- Gregory FioreExecutive Officer
- Matthew AngelDirector
- Offering amount
- $3M
- Amount sold
- $50K
- Minimum investment
- $25K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2021 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedFeb 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew AngelDirector
- Gregory FioreExecutive Officer
- Mark CorriganDirector
- Offering amount
- $3M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Exacis Biotherapeutics raised?
- Exacis Biotherapeutics has disclosed $1.2M raised across 2 rounds.
- Where is Exacis Biotherapeutics headquartered?
- Exacis Biotherapeutics is headquartered in Cambridge, US.